33 related articles for article (PubMed ID: 11441296)
1. Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma.
Lee SW; Kim YM; Lee HY; Kim DY; Kim JH; Nam JH; Kim YT
J Gynecol Oncol; 2010 Mar; 21(1):38-44. PubMed ID: 20379446
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of CD45RO(+) cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients.
Kryczek I; Gryboś M; Dlubek D; Klimczak A; Rabczyński J; Lange A
Cancer Immunol Immunother; 2002 Nov; 51(9):513-9. PubMed ID: 12357323
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract.
Lotzová E; Savary CA; Freedman RS; Bowen JM
Cancer Immunol Immunother; 1984; 17(2):124-9. PubMed ID: 6205745
[TBL] [Abstract][Full Text] [Related]
4. Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.
Allavena P; Lo Presti P; Di Bello M; Lucchini V; Lissoni A; Zanetta G; Mangioni C; Mantovani A
Cancer Immunol Immunother; 1988; 27(1):69-76. PubMed ID: 2969284
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.
Sheid B; Boyce J
Cancer Immunol Immunother; 1984; 17(3):190-4. PubMed ID: 6332671
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
Li YN; Li YY; Wang SX; Ma XY
Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer.
Świderska J; Kozłowski M; Gaur M; Pius-Sadowska E; Kwiatkowski S; Machaliński B; Cymbaluk-Płoska A
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204342
[TBL] [Abstract][Full Text] [Related]
8. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.
Batchu RB; Gruzdyn OV; Kolli BK; Dachepalli R; Umar PS; Rai SK; Singh N; Tavva PS; Weaver DW; Gruber SA
Adv Exp Med Biol; 2021; 1290():51-65. PubMed ID: 33559854
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor infiltrating natural killer cell subset.
Levi I; Amsalem H; Nissan A; Darash-Yahana M; Peretz T; Mandelboim O; Rachmilewitz J
Oncotarget; 2015 May; 6(15):13835-43. PubMed ID: 26079948
[TBL] [Abstract][Full Text] [Related]
10. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies.
Melichar B; Solichová D; Freedman RS
Int J Gynecol Cancer; 2006; 16(1):240-52. PubMed ID: 16445639
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal immune system in patients with advance epithelial ovarian cancer.
Wertel I; Nowicka A; Rogala E; Kotarski J
Int Rev Immunol; 2011; 30(2-3):87-101. PubMed ID: 21557636
[TBL] [Abstract][Full Text] [Related]
12. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries.
Melichar B; Tousková M; Tosner J; Kopecký O
Onkologie; 2001 Apr; 24(2):156-60. PubMed ID: 11441296
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
15. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
